The structure of cell-free DNA (cfDNA) is altered in the blood of patients with cancer. From
whole-genome sequencing, we retrieve the cfDNA fragment-end composition using a new …

Background Blood-based methods using cell-free DNA (cfDNA) are under development as
an alternative to existing screening tests. However, early-stage detection of cancer using …

Cell-free DNA (cfDNA) is short, extracellular, fragmented double-stranded DNA found in
plasma. Plasma of patients with solid tumor has been found to show significantly increased …

Background Plasma cell-free DNA (cfDNA) fragmentomics has demonstrated significant
differentiation power between cancer patients and healthy individuals, but little is known in …

Tumor-specific, circulating cell-free DNA (cfDNA) in liquid biopsy test is a novel promising
biomarker in the advancement of cancer management, including early diagnosis, screening …

Multiple studies have shown that cell-free DNA (cfDNA) from cancer patients differ in both
fragment length and fragment end motif (FEM) from healthy individuals, yet there is a lack of …

Colorectal cancer is frequently diagnosed in advanced stages, highlighting the need for
developing approaches for early detection. Liquid biopsy using cell-free DNA (cfDNA) …

The cumulative pool of cell-free DNA (cfDNA) molecules within bodily fluids represents a
highly dense and multidimensional information repository. This “biological mirror” provides …

Background Fragmentomics, the investigation of fragmentation patterns of cell-free DNA
(cfDNA), has emerged as a promising strategy for the early detection of multiple cancers in …

Purpose Access to genomic tumor material is required to select patients for targeted
therapies. However, tissue biopsies are not always feasible and therefore circulating cell …